ReviewArchives of osteoporosis2026
The contested association between MASLD and osteoporosis: a narrative review of heterogeneous evidence and modifying factors.
Review in Archives of osteoporosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) and osteoporosis are prevalent chronic metabolic disorders. Although a pathophysiological plausibility for their association exists, clinical evidence demonstrates substantial controversy and heterogeneity.
aimsFirst, review and critically evaluate the controversial evidence regarding their association; second, analyze the sources of research heterogeneity, elucidate the regulatory roles of key effect modifiers; and third, integrate shared pathophysiological mechanisms to provide insights for future research and clinical practice.
methodsWe conducted a literature search in PubMed, Embase, Cochrane Library, Scopus, and Web of Science up to September 16, 2025, using relevant keywords and terms.
resultsCurrent studies have reported varying associations between MASLD and bone mineral density, ranging from negative to null to positive. The relationship between MASLD and bone metabolism exhibits highly complex, conditional, and context-dependent characteristics. The strength and direction of this association may be significantly influenced by a range of effect modifiers, including gender, age, ethnicity, visceral fat distribution, the severity of MASLD, and the sites of skeletal measurement. Factors such as chronic inflammatory responses, insulin resistance, and adipokine dysregulation may be involved in modulating this association.
conclusionsThe association between MASLD and osteoporosis is highly complex, conditional, and context-dependent, as its direction and magnitude are significantly modulated by multiple effect modifiers. Future research requires large-scale, long-term, multicenter prospective cohort studies to thoroughly investigate their causal relationship and underlying mechanisms.
Indexed as
Identifiers
41524966What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.